Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.69 |
| ▸ | NOS1 | P29475 | 9/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4542003 | 1.00 | HSD17B10 (0.69) | HSD17B10NOS1AKR1B1KDM4EMEN1 | |
| SCHEMBL59520 | 1.00 | HSD17B10 (0.69) | HSD17B10NOS1AKR1B1KDM4EMEN1 | |
| SCHEMBL30287655 | 1.00 | HSD17B10 (0.69) | HSD17B10NOS1AKR1B1KDM4EMEN1 | |
| SCHEMBL13314521 | 1.00 | HSD17B10 (0.69) | HSD17B10NOS1AKR1B1KDM4EMEN1 | |
| SCHEMBL29776903 | 1.00 | HSD17B10 (0.69) | HSD17B10NOS1AKR1B1KDM4EMEN1 | |
| SCHEMBL29424531 | 1.00 | HSD17B10 (0.69) | HSD17B10NOS1AKR1B1KDM4EMEN1 | |
| Xylitol SCHEMBL18285153 | 0.96 | HSD17B10 (0.68) | HSD17B10NOS1AKR1B1KDM4EMEN1 | |
| Mannitol SCHEMBL21903100 | 0.96 | HSD17B10 (0.68) | HSD17B10NOS1AKR1B1KDM4EMEN1 | |
| Phosphoric Acid SCHEMBL1443736 | 0.95 | HSD17B10 (0.63) | HSD17B10NOS1AKR1B1 | |
| SCHEMBL12559328 | 0.90 | HSD17B10 (0.66) | HSD17B10NOS1AKR1B1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3380 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099249-A1 | MODIFIED AND UNMODIFIED PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) FOR USE IN SUBJECTS HAVING INCREASED AMYLOID-BETA AND/OR PHOSPHO-TAU-PROTEIN LOAD AND/OR NEUROINFLAMMATION | PAM THERAGNOSTICS GMBH (DE) | 2026-05-15 | — | — | WO | claimed |
| EP-4718076-A2 | WORKFLOW FOR RISK ASSESSMENT AND PATIENT MANAGEMENT USING PROCALCITONIN AND MIDREGIONAL-PROADRENOMEDULLIN | B.R.A.H.M.S GmbH (DE) | 2026-04-01 | — | — | EP | claimed |
| EP-3729101-B1 | WORKFLOW FOR RISK ASSESSMENT AND PATIENT MANAGEMENT USING PROCALCITONIN AND PROADRENOMEDULLIN | BRAHMS GMBH (DE) | 2026-03-18 | — | — | EP | claimed |
| US-20260042831-A1 | METHODS OF TREATING SARCOIDOSIS WITH A TNF-A ANTIBODY AND ASSOCIATED COMPOSITIONS AND METHODS | XENTRIA INC (US) | 2026-02-12 | — | — | US | claimed |
| US-12533428-B2 | Multimodal fluorine-CY3/5/7-DOTA-hapten compositions, diagnostics, fluorescence guided surgery and radioimmunotherapy | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-01-27 | — | — | US | claimed |
| US-20250362295-A1 | MARKER COMBINATIONS FOR DIAGNOSING INFECTIONS AND METHODS OF USE THEREOF | MEMED DIAGNOSTICS LTD. (IL) | 2025-11-27 | — | — | US | claimed |
| EP-4630056-A2 | METHODS OF TREATING SARCOIDOSIS WITH A TNF-A ANTIBODY AND ASSOCIATED COMPOSITIONS AND METHODS | Xentria, Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| US-20250268984-A1 | INTERFERON-BASED CANCER TREATMENT METHOD, AND PHARMACEUTICAL COMBINATION | XIAMEN AMOYTOP BIOTECH CO., LTD. (CN) | 2025-08-28 | — | — | US | claimed |
| US-20250258174-A1 | METHODS FOR PREDICTING THE RISK OF DEVELOPING MULTISYSTEM INFLAMMATORY SYNDROME (MIS) FOLLOWING EXPOSURE TO AN INFECTIOUS AGENT AND FOR DIAGNOSING MIS FOLLOWING EXPOSURE TO AN INFECTIOUS AGENT | HYCULT BIOTECH B.V. (NL) | 2025-08-14 | — | — | US | claimed |
| EP-3823650-B1 | FECAL MICROBIOTA COMPOSITION, FOR USE IN REDUCING TREATMENT-INDUCED INFLAMMATION | MAAT PHARMA (FR) | 2025-07-16 | — | — | EP | claimed |
| WO-1997005273-A1 | METHOD OF DETERMINING THE CONCENTRATION OF AN ENZYME BY PHOTOMETRIC MEASUREMENT OF THE ABSORPTION OF A DYE FORMED BY THE ENZYME IN A TEST SOLUTION | B.R.A.H.M.S DIAGNOSTICA GMBH (DE) | 1997-02-13 | — | — | WO | claimed |
| EP-0689541-B1 | PTERIN DERIVATIVES AND THEIR USE FOR THE PREPARATION OF IMMUNOASSAYS | BRAHMS DIAGNOSTICA GMBH (DE) | 1996-10-09 | — | — | EP | claimed |
| EP-0689541-A1 | PTERIN DERIVATIVES AND THEIR USE FOR THE PREPARATION OF IMMUNOASSAYS | BRAHMS DIAGNOSTICA GMBH (DE) | 1996-01-03 | — | — | EP | claimed |
| US-5439799-A | Composition for immunological determination of neopterin containing antibody and potassium or sodium hexacyanoferrate oxidizing agent to reduce interference by body fluids | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-08-08 | — | — | US | claimed |
| WO-1994021636-A1 | PTERIN DERIVATIVES AND THEIR USE FOR THE PREPARATION OF IMMUNOASSAYS | B.R.A.H.M.S DIAGNOSTICA GMBH (DE) | 1994-09-29 | — | — | WO | claimed |
| WO-1994006010-A1 | PROCESS AND DEVICE FOR IN-VITRO TESTING OF EFFECTS ON BIOLOGICAL STRUCTURES | TEICHMANN REINHARD (DE) | 1994-03-17 | — | — | WO | claimed |
| EP-0569768-A1 | Means and method for the treatment of body fluids for the determination of neopterin | MERCK PATENT GmbH (DE) | 1993-11-18 | — | — | EP | claimed |
| EP-0370960-A1 | Neopterin as a marker in a diagnostic screening test kit to detect retrovirus diseases | Pera, Ivo E. (US) | 1990-05-30 | — | — | EP | claimed |
| EP-0012444-B1 | DIAGNOSTIC METHOD, ESPECIALLY FOR THE EARLY RECOGNITION OF MALIGNANT TUMORS AND/OR VIRAL DISEASES, AND MEANS TO CARRY IT OUT | Wachter, Helmut, Univ.-Prof. Dr. (AT) | 1984-07-25 | — | — | EP | claimed |
| EP-0012444-A1 | Diagnostic method, especially for the early recognition of malignant tumors and/or viral diseases, and means to carry it out | Wachter, Helmut, Univ.-Prof. Dr. (AT) | 1980-06-25 | — | — | EP | claimed |